

DISCLAIMER



This document contains certain forward-looking statements concerning Danone. Although Danone believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of these risks and uncertainties, please refer to the section "Risk Factors" in Danone's Registration Document (which is available on www.danone.com). Danone undertakes no obligation to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy DANONE shares.

Due to rounding, the sum of values presented may differ from totals as reported. Such differences are not material.



H1 2014 HIGHLIGHTS



H1 2014
+2.2%
11.27% -159 bps
€ 286 mln

⁽¹⁾ Like-for-like: Based on constant scope of consolidation, constant exchange rates and accounting principles

⁽²⁾ Free cash-flow excluding exceptional items: cash-flows provided or used by operating activities less capital expenditure net of disposals, excluding acquisition costs related to business combinations and earn-outs related to business combinations and paid subsequently to acquisition date and before cash-flows related to initiatives that may be taken by the Group to deploy the plan to generate savings and adapt its organizations in Europe

H1 2014 KEY ACHIEVEMENTS



OVERCOME MILK INFLATION





Q1 margin under pressure as a result of record milk prices

Pricing, mix & cost management

→Q2 bounce back

Milk prices now stabilized / down

INNOVATION & MIX IN KEY MARKETS









NORAM/CIS: Tëma Biolact, Creamery & Oikos Frozen

ALMA: Nutrilon & Dumex International, VIT Levité

STRENGTHEN OUR STRATEGIC PLATFORMS








Closing of COFCO Mengniu partnership: Increased stake & Fresh Dairy JV

Strengthening Africa: 40% stake in Brookside (East Africa)

GEOGRAPHICAL DYNAMICS






DAIRY EUROPE: RECOVERY IN PROGRESS TO RESTORE CONDITIONS FOR PROFITABLE GROWTH



BREAKDOWN VOLUME/VALUE GROWTH (%)

Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 4.0% (4.0)% (8.0)% (12.0)% (16.0)%

VALUE MARKET SHARE EVOLUTION



RE-INVENT EUROPE TO CREATE POSITIVE DRIVERS






CIS: KEEP STRENGTHENING THE PORTFOLIO



RUSSIAN SALES BREAKDOWN






DECISION TO ADAPT COST STRUCTURE




NORAM: PUSHING THE CATEGORY GROWTH AGENDA THROUGH INNOVATIONS



LEADING THE YOGURT CATEGORY



CO-LEADING THE GREEK YOGURT SEGMENT



RECENT INNOVATIONS















ALMA: GROW AND DEVELOP SOLID PLATFORMS





ALMA: ENHANCE THE DANONE PLATFORM IN AFRICA



- ACCELERATE THE GROWTH OF DANONE'S PORTFOLIO
- EXPAND DANONE'S GEOGRAPHICAL FOOTPRINT



DANONE ACQUIRES A 40% INTEREST IN BROOKSIDE

East Africa's leading Dairy Products company

2013 revenues of around €130 million

Region's largest milk collection network (140,000 farmers)

Unique distribution platform serving the entire country











CHINA: KEEP TURNING ELN ENGINE BACK TO FULL SPEED



STRONG ACTIVATION CAMPAIGNS

Blue house exclusive launch at Walmart



Merchandising of Dumex Precinutri International



SUSTAINABILITY ENABLERS

Build category recognition

Master geographies and channels

Be the closest to mums

Efficient investment model to secure profitability

Secure global supply chain


ESTIMATED SALES RECOVERY PATH



H2 2014 AGENDA - DELIVER ON 2014 KEY PRIORITIES



TURNING AROUND EUROPE




KEEP WINNING CIS & NORAM



GROW AND NAVIGATE IN ALMA



TURN ELN ENGINE BACK TO FULL SPEED





H1 2014 - KEY FIGURES



Sales	€10,467 mln	+2.2% like-for-like ⁽¹⁾ -5.3% reported
Trading operating income	€1,180 mln	-10.0% like-for-like ⁽¹⁾ -20.0% reported
Trading operating margin	11.27%	-159 bps like-for-like ⁽¹⁾ -207 bps reported
Underlying net income	€683 mln	-11.5% like-for-like ^{(1) (2)} -21.9% reported
Underlying EPS (fully diluted)	€ 1.16	-11.1% like-for-like ⁽¹⁾ -21.5% reported
Free cash-flow excluding exceptional items ⁽³⁾	€286 mln	-59.9% reported


⁽¹⁾ Like-for-like: Based on constant scope of consolidation and constant exchange rates

⁽²⁾ Excluding non-current

⁽³⁾ Free cash-flow excluding exceptional items: cash flows provided or used by operating activities less capital expenditure net of disposals and excluding acquisition costs related to business combinations and before cash-flows related to initiatives that may be taken by the Group to deploy the plan to generate savings and adapt its organizations in Europe


H1 2014 - SALES GROWTH ANALYSIS





Q2 2014 - SALES GROWTH ANALYSIS







TOTAL GROUP – SOLID UNDERLYING TRENDS ON HIGH COMPS



Like-for-like sales growth per quarter



Like-for-like sales growth per semester



- Strong impact of the Fonterra false alert
- Underlying topline remains solid




FRESH DAIRY PRODUCTS - VALUE DRIVEN GROWTH






Like-for-like sales growth per semester

Like-for-like sales growth per quarter





- * Price/volume rebalancing to handle with milk inflation
- Innovation driving mix up

FRESH DAIRY PRODUCTS - SELECTED INNOVATIONS Q2


















WATERS - SUSTAINED STRONG GROWTH










Like-for-like sales growth per semester



- Solid volume growth in all regions
- Balanced growth with positive mix driven by Aquadrinks

WATERS - SELECTED INNOVATIONS Q2

















EARLY LIFE NUTRITION - SOLID UNDERLYING GROWTH







Like-for-like sales growth per semester



- * Asia recovery initiatives in line with objectives
- Solid dynamics in the Rest of the World

EARLY LIFE NUTRITION - SELECTED INNOVATIONS Q2





China








Jumbo pack Blédilait croissance France




MEDICAL NUTRITION - SUSTAINED GROWTH



Like-for-like sales growth per quarter



Like-for-like sales growth per semester



- * Solid performance driven by volume growth
- Growth across all categories



MEDICAL NUTRITION - SELECTED INNOVATIONS Q2









Roll-out of Souvenaid
Poland, Sweden, Finland &
Switzerland


TRADING OPERATING INCOME AND MARGIN



€ mIn	H1 2013	H1 2014
Trading operating income	1,475	1,180
Other operating items	(291)	(96) ⁽¹⁾
Operating income	1,184	1,084
Trading operating margin	13.34%	11.27%

H1 2014 - MARGIN DEVELOPMENT






H1 2014 - MARGIN DEVELOPMENT



LIKE-FOR-LIKE MARGIN BRIDGE



RECORD MILK PRICES



DANONE FARMGATE PRICE (€/TON)



TRADING OPERATING MARGIN by business lines & geographical areas



	H1 2013	H1 2014	Like-for-like change
Fresh Dairy Products	9.91%	7.81%	(168) bps
Waters	13.18%	12.50%	+38 bps
Early Life Nutrition	20.49%	17.42%	(270) bps
Medical Nutrition	19.31%	17.56%	(92) bps
Europe	14.28%	14.56%	+60 bps
CIS+Noram	9.36%	7.23%	(121) bps
ALMA	14.56%	10.09%	(401) bps
Total	13.34%	11.27%	(159) bps


FROM OPERATING INCOME TO EPS



€ mIn	H1 2013 underlying	H1 2014 underlying	Non-current items	H1 2014
Trading operating income	1,475	1,180		1,180
Other operating items	-	-	(96)	(96)
Operating income	1,475	1,180	(96)	1,084
Total financial expenses	(152)	(156)	(3)	(159)
Income tax	(402)	(303)	19	(284)
Net income of affiliates	38	25	1	26
Net income	959	746	(79)	666
of which non-controlling interests	86	63	(5)	59
Net income - Group share	873	683	(75)	608
Fully diluted number of shares mln	592	589		
Fully diluted underlying EPS €	€ 1.48	€ 1.16		

H1 2014 - ANALYSIS OF UNDERLYING FULLY DILUTED EPS GROWTH






CASH DRIVERS




FREE CASH-FLOW EXCLUDING EXCEPTIONAL ITEMS (€ MLN)



WORKING CAPITAL (€ MLN)


June 30, 2013 December 31, 2013 June 30, 2014 -1,382 -1,768 -1,768 -7.0%

CAPITAL EXPENDITURES (€ MLN)




H1 2014 - FCF TO NET DEBT CHANGE





SYNTHETIC BALANCE SHEET





⁽¹⁾ Excluding assets included in net debt

⁽²⁾ Net of cash, cash equivalents, marketable securities, other short term investments and financial instrument assets



2014 GUIDANCE




	2014 objectives
Sales growth ⁽¹⁾	+4.5% to +5.5%
Trading operating margin ⁽¹⁾	Stable ± 20 bps
Free cash-flow excluding exceptional items ⁽²⁾	around €1.5 bn

⁽¹⁾ Like-for-like: Based on constant scope of consolidation, constant exchange rates and accounting principles

⁽²⁾ Free cash-flow excluding exceptional items: cash-flows provided or used by operating activities less capital expenditure net of disposals, excluding acquisition costs related to business combinations and paid subsequently to acquisition date and before cash-flows related to initiatives that may be taken by the Group to deploy the plan to generate savings and adapt its organizations in Europe

2014 - AN UNBALANCED YEAR





- Negative effect of the 2013 comparison base and carryover of the Fonterra crisis
- Strong rebound expected in H2 2014

H2 2014 AGENDA




DELIVER ON 2014 PRIORITIES

BRING DANONE BACK TO THE AGENDA OF A ...



KEEP WINNING CIS & NORAM





TURN ELN ENGINE BACK TO FULL SPEED







TAX RATE DEVELOPMENT



€mIn	H1 2013	H1 2014
Total income tax (reported)	(315)	(284)
Reported tax rate	29.0%	30.7%
Non-current income tax ⁽¹⁾	87	19
Current income tax	(402)	(303)
Underlying tax rate	30.3%	29.6%

(1) Tax related to non-current items

SHARE PRICE & SHAREHOLDING




DANONE H1 2014 SHARE PRICE EVOLUTION




DANONE H1 2014 STOCK PERFORMANCE (June 30)

Absolute	+3.7%
Relative vs. CAC 40	+0.7%
Relative vs. Eurostoxx 50	-0.4%

SHAREHOLDING BY INVESTOR (1)



INSTITUTIONAL SHAREHOLDING BY GEOGRAPHY (1)



Q2 2014 - IMPACT OF CURRENCIES AND SCOPE



	Fresh Dairy Products	Waters	Early Life Nutrition	Medical Nutrition	Total
Reported sales growth	(7.8)%	+6.8%	(13.6)%	+4.3%	(5.5)%
Currency	(8.6)%	(8.2)%	(6.4)%	(3.4)%	(7.8)%
Scope of consolidation	(1.6)%	+1.9%	+2.0%	+0.4%	(0.0)%
Like-for-like sales growth	+2.4%	+13.1%	(9.2)%	+7.3%	+2.3%

H1 2014 - IMPACT OF CURRENCIES AND SCOPE



	Fresh Dairy Products	Waters	Early Life Nutrition	Medical Nutrition	Total
Reported sales growth	(6.3)%	+4.1%	(13.1)%	+3.1%	(5.3)%
Currency	(9.3)%	(8.9)%	(6.6)%	(3.7)%	(8.3)%
Scope of consolidation	(0.1)%	+1.8%	+1.9%	+0.5%	+0.8%
Like-for-like sales growth	+3.1%	+11.2%	(8.4)%	+6.3%	+2.2%

Q2 2014 - SALES BY BUSINESS & GEOGRAPHICAL AREA



€ mIn	Q2 2013	Q2 2014	Like-for-like sales growth
Fresh Dairy Products	3,071	2,831	+2.4%
Waters	1,104	1,179	+13.1%
Early Life Nutrition	1,206	1,042	(9.2)%
Medical Nutrition	339	354	+7.3%
Europe	2,155	2,208	+0.1%
CIS+Noram	1,197	1,176	+7.0%
ALMA	2,368	2,022	+2.0%
Total	5,720	5,406	+2.3%

H1 2014 - SALES BY BUSINESS & GEOGRAPHICAL AREA



€ mIn	H1 2013	H1 2014	Like-for-like sales growth
Fresh Dairy Products	6,023	5,640	+3.1%
Waters	1,991	2,074	+11.2%
Early Life Nutrition	2,383	2,071	(8.4)%
Medical Nutrition	661	682	+6.3%
Europe	4,160	4,261	+0.3%
CIS+Noram	2,360	2,330	+7.4%
ALMA	4,538	3,876	+1.3%
Total	11,058	10,467	+2.2%

Q2 2014 LIKE-FOR-LIKE SALES GROWTH Breakdown volume/value



Like-for-like	Volume	Price/mix	Total
Fresh Dairy Products	(7.4)%	+9.8%	+2.4%
Waters	+7.0%	+6.1%	+13.1%
Early Life Nutrition	(7.9)%	(1.3)%	(9.2)%
Medical Nutrition	+6.2%	+1.1%	+7.3%
Europe	(2.3)%	+2.4%	+0.1%
CIS+Noram	(9.0)%	+16.0%	+7.0%
ALMA	(3.4)%	+5.4%	+2.0%
Total	(3.9)%	+6.2%	+2.3%

H1 2014 LIKE-FOR-LIKE SALES GROWTH Breakdown volume/value




Like-for-like	Volume	Price/mix	Total
Fresh Dairy Products	(5.7)%	+8.8%	+3.1%
Waters	+6.2%	+5.0%	+11.2%
Early Life Nutrition	(6.4)%	(2.0)%	(8.4)%
Medical Nutrition	+5.3%	+1.0%	+6.3%
Europe	(1.4)%	+1.7%	+0.3%
CIS+Noram	(6.4)%	+13.8%	+7.4%
ALMA	(3.2)%	+4.5%	+1.3%
Total	(3.0)%	+5.2%	+2.2%

H1 2014 - CASH BRIDGE



€ mIn



CHANGES IN EXCHANGE RATES 28.8% of sales denominated in €



(% to	otal	
H1	14	sal	es

H1 14 vs H1 13 (avg) Q2 14 vs Q2 13 (avg)

Russian ruble
US dollar
Chinese yuan
Indonesian rupiah
Mexican peso
British pound
Brazilian real
Argentine peso
Polish zloty
Moroccan dirham

10.1%
10.1%
6.5%
5.3%
5.3%
5.2%
4.5%
3.8%
2.8%
2.8%

(15.2)%
(4.2)%
(3.8)%
(20.4)%
(8.2)%
3.6%
(15.3)%
(37.3)%
0.1%
(0.8)%

(13.8)%)
(4.8)%	
(5.9)%	
(8.5)%	
(19.8)%)
4.4%)
(11.7)%)
(38.1)%)
(0.8)%)
0.8%)

